Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 24, 2016 12:25 ET | Source: AIM ImmunoTech Inc.

UPDATE -- Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe

PHILADELPHIA, May 24, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based...
May 23, 2016 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe

PHILADELPHIA, May 23, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based...
May 16, 2016 17:09 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2016

The company is now focusing on commercial success by seeking co-development partners and working closely with the research and regulatory communities to bring disease fighting technologies to the...
May 12, 2016 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Conference Call to Provide Quarterly Business Update on May 17, 2016

PHILADELPHIA, May 12, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it anticipates filing its 2016 first quarter...
April 20, 2016 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Retains Huron Consulting Group to Support Partnering Strategy and Planning for Alferon® and Ampligen®

PHILADELPHIA, April 20, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) (the "Company” or "Hemispherx”) announced that it has signed a consulting agreement with Huron Consulting...
April 19, 2016 03:00 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Enters into Alfa-n3 Interferon Clinical Trial, Sales, Marketing, Distribution, and Supply Agreement with Saudi Arabia’s Premier Pharma Company in Fight Against the Deadly MERS Disease

PHILADELPHIA, April 19, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the Company) announced today that it has entered into a Clinical Trial, Sales, Marketing, Distribution,...
April 04, 2016 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Enters into Alfa-n3 Interferon Clinical Trial, Sales, Marketing, Distribution, and Supply Agreement with Saudi Arabia’s Premier Pharma Company in Fight Against the Deadly MERS Disease

PHILADELPHIA, April 04, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the Company) announced today that it has entered into a Clinical Trial, Sales, Marketing, Distribution,...
March 29, 2016 17:41 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2015

Hemispherx Biopharma Management Team: Reflects Company’s Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder ValueConference...
March 22, 2016 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Announces Conference Call to Discuss Management Changes and Provide Corporate Update on March 30, 2016

PHILADELPHIA, March 22, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced today that it anticipates releasing its 2015 year-end financial...
March 10, 2016 08:30 ET | Source: AIM ImmunoTech Inc.

Hemispherx Biopharma Reviews Ampligen® Data With National Institute of Neurological Disorders and Stroke (NINDS)

PHILADELPHIA, March 10, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announced that the strong commitment by the National Institutes of Health (NIH)...